Hemorrhage
Conditions
Keywords
Hemostasis
Brief summary
The objective of this study is to evaluate the safety and and hemostatic effectiveness of the Fibrin Pad (FP) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.
Interventions
BIOLOGICALFibrin Pad
Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
PROCEDUREStandard of Care
Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.
Sponsors
OMRIX Biopharmaceuticals
Ethicon, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects \> 18 years of age, requiring elective or urgent, open hepatic surgery * Presence of an appropriate bleeding hepatic parenchymal Target Bleeding Site (TBS) as identified intra-operatively by the surgeon * Subjects must be willing to participate in the study, and provide written informed consent
Exclusion criteria
* Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure * TBS is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of the FP to blood flow and pressure during healing and absorption of the product * TBS with major arterial bleeding requiring suture or mechanical ligation * Subjects admitted for trauma surgery * Subject is a transplant patient for fulminant hepatic failure * Subject with TBS within an actively infected field * Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine * Subjects with known intolerance to blood products or to one of the components of the study product or is unwilling to receive blood products * Subjects who are known, current alcohol and / or drug abusers * Subjects who have participated in another investigational drug or device research study within 30 days of surgery * Female subjects who are pregnant or nursing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of subjects achieving hemostasis at the Target Bleeding Site (TBS). | Intra-operative |
Secondary
| Measure | Time frame |
|---|---|
| Absolute time to hemostasis | Intraoperative |
| Subjects requiring re-treatment | Intraoperative |
| Proportion of subjects achieving hemostasis success at 10-minutes following randomization. | Intra-operative |
| Incidence of adverse events potentially related to thrombotic events | Intraoperative through 60 days |
| Incidence of adverse events | Intraoperative through 60 days |
| Incidence of adverse events potentially related to re-bleeding at TBS | Intraoperative through 60 days |
Countries
Australia, Germany, Netherlands, New Zealand, United Kingdom
Outcome results
None listed